KR101964954B1 - 뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도 - Google Patents

뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도 Download PDF

Info

Publication number
KR101964954B1
KR101964954B1 KR1020137008259A KR20137008259A KR101964954B1 KR 101964954 B1 KR101964954 B1 KR 101964954B1 KR 1020137008259 A KR1020137008259 A KR 1020137008259A KR 20137008259 A KR20137008259 A KR 20137008259A KR 101964954 B1 KR101964954 B1 KR 101964954B1
Authority
KR
South Korea
Prior art keywords
disease
compound
compound according
pharmaceutically acceptable
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137008259A
Other languages
English (en)
Korean (ko)
Other versions
KR20130106384A (ko
Inventor
파블로 빌로스라다
앤젤 메젠구어
Original Assignee
바이오뉴레 파르마, 에스.엘.
콘세호 수페리오르 데 인베스티가시오네스 시엔티피카스
인스티튜트 디＇인베스티가시온스 바이오메디퀘스 아우구스트 피 아이 수니에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오뉴레 파르마, 에스.엘., 콘세호 수페리오르 데 인베스티가시오네스 시엔티피카스, 인스티튜트 디＇인베스티가시온스 바이오메디퀘스 아우구스트 피 아이 수니에르 filed Critical 바이오뉴레 파르마, 에스.엘.
Publication of KR20130106384A publication Critical patent/KR20130106384A/ko
Application granted granted Critical
Publication of KR101964954B1 publication Critical patent/KR101964954B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020137008259A 2010-08-31 2011-08-31 뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도 Active KR101964954B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37882310P 2010-08-31 2010-08-31
US61/378,823 2010-08-31
PCT/IB2011/002562 WO2012028959A1 (en) 2010-08-31 2011-08-31 Agonists of neurotrophin receptors and their use as medicaments

Publications (2)

Publication Number Publication Date
KR20130106384A KR20130106384A (ko) 2013-09-27
KR101964954B1 true KR101964954B1 (ko) 2019-04-03

Family

ID=45048148

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137008259A Active KR101964954B1 (ko) 2010-08-31 2011-08-31 뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도

Country Status (19)

Country Link
US (3) US8791076B2 (https=)
EP (1) EP2611775B8 (https=)
JP (1) JP5946454B2 (https=)
KR (1) KR101964954B1 (https=)
CN (1) CN103270022B (https=)
AU (1) AU2011298091B2 (https=)
BR (1) BR112013004662B8 (https=)
CA (1) CA2809774C (https=)
DK (1) DK2611775T3 (https=)
ES (1) ES2575684T3 (https=)
HR (1) HRP20160553T1 (https=)
HU (1) HUE029393T2 (https=)
IL (1) IL224972A (https=)
MX (1) MX340233B (https=)
PL (1) PL2611775T3 (https=)
PT (1) PT2611775E (https=)
RU (1) RU2606622C2 (https=)
SI (1) SI2611775T1 (https=)
WO (1) WO2012028959A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
WO2012028959A1 (en) 2010-08-31 2012-03-08 Pablo Villoslada Agonists of neurotrophin receptors and their use as medicaments
US20160193296A1 (en) * 2012-12-19 2016-07-07 Brown University Methods for treatment of microcephaly associated autism disorders
ES2699410T3 (es) * 2014-05-28 2019-02-11 Univ Dresden Tech Ensayo basado en células y métodos de cribado de moduladores de la señalización de p75NTR
WO2018039641A1 (en) * 2016-08-25 2018-03-01 Pharmatrophix, Inc. Methods and compounds for treating alcohol use disorders and associated diseases
KR101821118B1 (ko) 2016-09-06 2018-01-23 가톨릭대학교 산학협력단 감보그 산(gambogic acid)을 포함한 알러지성 질환 예방 또는 치료용 조성물
CN107802823A (zh) * 2017-10-27 2018-03-16 胡军 Sh2b衔接蛋白1在治疗帕金森病中的功能应用
US11897928B2 (en) 2018-07-18 2024-02-13 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
MX2021006527A (es) 2018-12-05 2021-07-21 Scohia Pharma Inc Compuesto macrociclico y su uso.
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
JP2022547640A (ja) * 2019-09-03 2022-11-14 ピーター ジェイ． シークマイヤー， 抗精神病薬療法に応答性の患者の同定および処置のための機器および方法
TW202131914A (zh) * 2019-10-30 2021-09-01 西班牙商布爾奴爾法碼有限公司 用於神經疾病或病狀的治療之新治療方案
TW202342494A (zh) 2022-03-30 2023-11-01 日商肽夢想股份有限公司 具有TrkB結合活性之肽複合物
KR20250127289A (ko) * 2022-12-22 2025-08-26 오쿨리스 오퍼레이션즈 에스에이알엘 신경영양인자 소분자 작용제의 합성
EP4671235A1 (en) * 2024-06-26 2025-12-31 Oculis Operations Sàrl SYNTHESIS OF SMALL MOLECULE NEUROTROPHIN AGONISTS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU189214B (en) 1983-01-20 1986-06-30 Alkaloida Vegyeszeti Gyar,Hu Process for preparing pyrroline and pyrrolidine carboxamide derivatives
US6271205B1 (en) 1994-09-21 2001-08-07 University Of Massachusetts Medical Center Cancer treatment by expression of differentiation factor receptor
US5747458A (en) 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
US6391871B1 (en) 1996-09-20 2002-05-21 John W. Olney Preventing neuronal degeneration in Alzheimer's disease
DE19751062A1 (de) 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6124361A (en) 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
HU229494B1 (en) 2000-05-04 2014-01-28 Basf Ag Uracil substituted phenyl sulfamoyl carboxamides
ES2169690B1 (es) * 2000-10-06 2004-03-16 Diverdrugs Sl Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.
ES2169691B1 (es) * 2000-10-11 2004-03-16 Diverdrugs Sl Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen.
DE60335743D1 (de) 2002-11-20 2011-02-24 Neuronova Ab Verbindungen und verfahren zur erhöhung der neurogenese
DE10303229B4 (de) 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen
US20110052603A1 (en) 2006-10-06 2011-03-03 The Walter And Eliza Hall Institute Of Medical Research method of treatment and agents useful for same
EP1994944A1 (en) * 2007-05-21 2008-11-26 Laboratorios SALVAT, S.A. Polymer conjugate compounds for the inhibition of apoptosis
ES2543222T3 (es) 2008-09-24 2015-08-17 Ribomic Inc. Aptámero para NGF y uso del mismo
RU2410392C2 (ru) * 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf
EP2289886A1 (en) 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
EP2289882A1 (en) 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer 3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments
WO2012028959A1 (en) 2010-08-31 2012-03-08 Pablo Villoslada Agonists of neurotrophin receptors and their use as medicaments

Also Published As

Publication number Publication date
HUE029393T2 (en) 2017-03-28
MX2013002329A (es) 2013-07-29
CA2809774C (en) 2019-03-05
US20170121367A1 (en) 2017-05-04
HRP20160553T1 (hr) 2016-09-23
KR20130106384A (ko) 2013-09-27
IL224972A (en) 2015-05-31
WO2012028959A1 (en) 2012-03-08
US10106577B2 (en) 2018-10-23
SI2611775T1 (sl) 2017-01-31
JP2013536833A (ja) 2013-09-26
EP2611775B1 (en) 2016-03-16
CN103270022B (zh) 2015-08-19
MX340233B (es) 2016-07-01
CN103270022A (zh) 2013-08-28
US20150005239A1 (en) 2015-01-01
RU2013113634A (ru) 2014-10-10
EP2611775A1 (en) 2013-07-10
AU2011298091B2 (en) 2015-08-20
US20120052094A1 (en) 2012-03-01
PL2611775T3 (pl) 2016-11-30
RU2606622C2 (ru) 2017-01-10
US8791076B2 (en) 2014-07-29
BR112013004662A2 (pt) 2016-08-02
PT2611775E (pt) 2016-06-07
BR112013004662B8 (pt) 2021-12-28
EP2611775B8 (en) 2016-06-08
JP5946454B2 (ja) 2016-07-06
AU2011298091A1 (en) 2013-04-18
CA2809774A1 (en) 2012-03-08
BR112013004662B1 (pt) 2021-09-28
DK2611775T3 (en) 2016-06-27
US9453047B2 (en) 2016-09-27
ES2575684T3 (es) 2016-06-30

Similar Documents

Publication Publication Date Title
KR101964954B1 (ko) 뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도
TWI776886B (zh) Sestrin-gator2交互作用之調節劑及其用途
Zhang et al. RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-β42-induced memory deficits in mice
RU2383547C2 (ru) Модуляция бета-катенин/tcf-активируемой транскрипции
Koppal et al. S100B proteins that lack one or both cysteine residues can induce inflammatory responses in astrocytes and microglia
KR20240055788A (ko) 신규한 ras 억제제
HK1258231A1 (zh) 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法
US20120237552A1 (en) Peptoid Agonists of Nerve Growth Factor and Their Use as Medicaments
US20160040126A1 (en) Regulation of differentiation into dopaminergic neurons by metalloprotease
JP2023517768A (ja) ＭＳ療法のためのκオピオイド受容体リガンドと組み合わしてのシクロチド
KR20220142363A (ko) 선택적 mTORC2 저해제 및 이의 용도
JP2011510976A (ja) イノシトール１，４，５−三リン酸受容体サブタイプ３の阻害用の組成物
CN114181201B (zh) 作为针对各种神经退行性疾病的潜在治疗剂的新化合物
KR20200018955A (ko) Grp75 단백질을 유효성분으로 포함하는 신경 손상 질환 예방 또는 치료용 조성물
WO2017075313A1 (en) Furostan-3-ol derivatives as skeletal muscle hypertrophic agents
Yu et al. Thrombospondin1 Enhanced Neuronal Wnt7a and CNTF Expressions by TNFα Signaling Pathway
WO2006090555A1 (ja) Akt活性化剤
JPWO2001073024A1 (ja) 神経栄養因子の発現誘導剤
JP2008044884A (ja) 神経細胞の軸索伸長方法及びストレス耐性付与方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20220310

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8